Previous close | 18.42 |
Open | 18.13 |
Bid | 18.06 x 100 |
Ask | 18.19 x 100 |
Day's range | 17.84 - 18.17 |
52-week range | 4.18 - 19.50 |
Volume | |
Avg. volume | 375,895 |
Market cap | 2.733B |
Beta (5Y monthly) | 0.61 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.49 |
Earnings date | 07 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 15.37 |
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...
PLANEGG/MUNICH, Germany, April 29, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.